Jacob "Jack" J.H. Bleesing, MD, PhD
- Co-Director, Diagnostic Immunology Laboratories
- Associate Director, Immunodeficiency and Histiocytosis Program
- Professor, UC Department of Pediatrics
- jack.bleesing@cchmc.org
- Board Certified
About
MD: University of Leiden, Leiden, The Netherlands, 1989.
PhD: University of Leiden, Leiden, The Netherlands, 2002.
Residency: Pediatrics, University of Florida, Gainesville, Florida, 1993.
Fellowship: Allergy/Immunology, Duke University Medical Center, Durham, North Carolina, 1995.
Fellowship: Clinical Laboratory Immunology, National Institutes of Health, Bethesda, Maryland, 2001.
Interests
Immunobiology; translational research; immunologic methods development
Services and Specialties
- Autoinflammatory Disease
- Bone Marrow Transplant
- Cancer and Blood Diseases Institute
- Cancer and Blood Diseases Clinical Labs
- Diagnostic Center for Heritable Immunodeficiencies
- Hemophagocytic Lymphohistiocytosis (HLH)
- Immune Deficiency and Histiocytosis
- Leukemia and Lymphoma
- Rare Lung Disease Program
- Genetics and Genomics Diagnostic Laboratory
Interests
Clinical investigation of primary immunodeficiency disorders (with emphasis on disorders of immuno dysregulation and B-cell disorders); immuno-reconstitution following blood and marrow transplantation; diagnostic immunology (with emphasis on flow cytometry)
Additional Languages
Dutch, German
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Factors associated with and kinetics of anti-IFN-α autoantibodies in RAG1/2 deficiency. Journal of Allergy and Clinical Immunology: Global. 2025; 4:100521.
Lipopolysaccharide-responsive and beige-like anchor protein (LRBA) functional deficiency caused by biallelic LRBA missense variants characterized by Evans syndrome or colitis. Journal of Allergy and Clinical Immunology. 2025; 156:270-278.
A Novel Dominant Negative Variant in IL2RG Gene that Failed to Be Corrected by Lentiviral Gene Therapy. 2025; 1.
Validation of an Interferon Type I Score Test on the Nanostring nCounter Platform. 2025; 1.
Clinical and Analytical Validation of a NOD2 Functional Test for XIAP/XLP2 Diagnosis. 2025; 1.
Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure. 2025; 1.
Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity. 2025; 1.
The Fas-mediated apoptosis assay: From concept to clinical application. Journal of Immunological Methods. 2025; 537:113812.
Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome - Impact of Age, Donor, and Infection: A Pidtc Report. Transplantation and Cellular Therapy. 2025; 31:s39-s41.
Diagnostic testing for hemophagocytic lymphohistiocytosis. Journal of Immunological Methods. 2025; 537:113816.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey